Showing results (371-380 of 536) with videos related to
Sort By:
Pageof 54
Metabolism: Clinical and Experimental|December 9, 2014
ACE2 deficiency shifts energy metabolism towards glucose utilizationStella Bernardi, Christos Tikellis, Riccardo Candido, et al.Kidney International|September 2, 2017
Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozinDavid Z I Cherney, Mark E Cooper, Ilkka Tikkanen, et al.Clinical Science (London, England : 1979)|May 19, 2016
Differential effects of NOX4 and NOX1 on immune cell-mediated inflammation in the aortic sinus of diabetic ApoE-/- miceElyse Di Marco, Stephen P Gray, Phyllis Chew, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 29, 2024
Urine Albumin-Creatinine Ratio Variability in People With Type 2 Diabetes: Clinical and Research ImplicationsNatasha Rasaratnam, Agus Salim, Irene Blackberry, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 12, 2015
Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 DiabetesMark E Cooper, Vlado Perkovic, Janet B McGill, et al.Diabetologia|May 12, 2016
The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosisBryna S M Chow, Christine Koulis, Pooja Krishnaswamy, et al.Clinical Science (London, England : 1979)|September 30, 2015
miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7Aaron D McClelland, Michal Herman-Edelstein, Radko Komers, et al.The American Journal of Pathology|January 1, 2003
The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studiesChristina J Moravski, Sandford L Skinner, Anthony J Stubbs, et al.Clinical Science (London, England : 1979)|January 20, 2022
Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney diseaseJakob A Østergaard, Jay C Jha, Arpeeta Sharma, et al.Journal of Hypertension|December 13, 2018
Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuriaMark E Cooper, Vlado Perkovic, Per-Henrik Groop, et al.Pageof 54